Skip to main content

You’ve been accepted to the Enhancing Oncology Model. Now what?

Doctor with stethoscope holding patient's hand

The Centers for Medicare and Medicaid Services Innovation Center recently announced approved applicants for the new Enhancing Oncology Model. If your facility has been selected by CMS, are you still weighing your options during the current baseline evaluation period? 

Two deciding factors may include the program data that CMS provides and whether EOM is enough of an improvement over the prior Oncology Care Model to make your investment worthwhile.

Another factor to consider: Will you have the resources in place to conduct a baseline evaluation before EOM’s program start on July 1, 2023?

How EOM differs from OCM

EOM aims to improve the coordination of oncology care, drive practice transformation and reduce Medicare fee-for-service spending through episode-based payment. It includes three major updates:

  • Fewer cancer types. Compared with OCM’s 21, EOM will be limited to seven common cancer types: breast, prostate, lung, small intestine/colorectal, multiple myeloma, lymphoma and chronic leukemia.
  • Revised baseline price prediction module. It now models prices separately for each of the seven cancer types. Additionally, the impact of comorbidities is modeled with increased specificity, the experience adjustment will take into account practice and regional variability, and the trend factor and novel therapy adjustments have been made cancer-type specific.
  • Immediate downside risk requirement. EOM requires participants to take on one of two downside risk arrangements immediately.

For more details on how EOM and OCM differ, read DataGen’s September blog. To see DataGen's key findings and in-depth analysis of EOM’s national baseline and prediction module methodology, watch our recorded webinar.

How to prepare

If these changes sound good, it’s time to prepare. DataGen recommends these five steps:

  1. Opt in to receive all program data. When CMS releases EOM participation agreements, opt in for all available data, which under OCM included claims-level data for specific episodes of care.
  2. Be ready to process data upon receipt. Have the internal resources or a contracted data vendor in place to begin baseline evaluation before EOM begins. CMS will provide data in the second quarter of 2023.
  3. Ensure clinical buy-in. If your practice has established EOM oncology stakeholders/physician champions, you’re more likely to be successful and navigate clinical changes well.
  4. Evaluate the target price. Can you deliver episode expenditures that are lower than model targets? Additional EOM differences may make that more likely, including underlying baseline prediction models, trend factors and novel therapy adjustments that are priced separately for each of the seven cancer types.
  5. Evaluate expenditures and utilization. Part D drugs, oncology care’s biggest cost driver, will be important. OCM risk adjustment didn’t control drug costs well or very much at all, but EOM’s design may assist your practice more.

How to decide

You become an official EOM participant after signing your participation agreement. This gives you time to evaluate any additional data that help with decision-making. You can stop participating with no risk, effective immediately, at any point prior to the model’s go-live date on July 1, 2023.

The practices that ultimately choose not to participate ­— including those that were a part of OCM — may not see EOM as enough of an improvement to make immediate downside financial risk worthwhile. Those that do participate generally believe they can succeed under the model and want to be at the forefront of oncology care and payment transformation.

Which group will you be in?

Need help with your EOM baseline evaluation? DataGen can provide key insight and consultation to help ensure the best performance, locking in better patient and financial outcomes and ensuring program success.

Comments

Popular posts from this blog

Alternative payment models: Strategies for success

In this edition of DataGen Insights, we look at how alternative payment model participants can ensure their processes and workflows are optimally set up for success. To help, DataGen listed the top three strategies all providers participating in APMs can employ and created a handy checklist to enable maximum returns and reduce financial risk. Please explore our website to learn more about our  products and services .  Download DataGen Insights today .  We hope you enjoy!

Why it's critical for Primary Care First participants to control and understand leakage

Patients' primary care visits outside of their attributed primary care office, also called “leaked” patient visits, can have unintended consequences for Primary Care First participants. Beginning July 2022, PCF Cohort 1 will face a reduction in population-based payments based on their leakage rate. The payment adjustment will be based on their 2021 claims data and will roll forward quarterly. To calculate your leakage rate, divide the number of qualifying visits and services your attributed beneficiaries have made to care centers outside of your practice (for example, visits to urgent care centers) by the total number of qualifying visits and services your attributed beneficiaries have made. Calculating primary care leakage with claims data alone comes with some unintended challenges. Unfortunately, some circumstances can unfairly and negatively impact a practice’s leakage rate: Nuances classifying care delivered by provider team members: It’s difficult to distinguish

CMMI’s New Enhancing Oncology Model – Deadline Approaching

As the final at-risk period for the Oncology Care Model was closing at the end of June, the Center for Medicare and Medicaid Innovation announced its new Enhancing Oncology Model (EOM). EOM aims to improve the coordination of oncology care, drive practice transformation and reduce Medicare fee-for-service spending through episode-based payment.  What is EOM? EOM is a voluntary, five-year model set to begin July 1, 2023. Patients undergoing chemotherapy for the treatment of cancer will trigger six-month episodes of care.  Eligible EOM participants include physician group practices with at least one Medicare-enrolled physician or a non-physician practitioner who furnishes evaluation and management services to Medicare beneficiaries receiving chemotherapy for cancer treatment.  EOM participants are required to implement eight participant redesign activities to drive care transformation in their practice. Examples include the provision of patient navigation, 24/7 access to an appropriate c